Table 2.

Baseline and final mineral-related biochemical changes

CharacteristicsCholecalciferolDoxercalciferolBetween-Treatment Group Pa
Baseline (n = 22)Final (n = 20)Pre-Post PBaseline (n = 25)Final (n = 20)Pre-Post P
Vitamin D (25(OH)D), ng/ml14.0 ± 6.137.2 ± 10.1<0.00115.1 ± 5.514.0 ± 6.10.59<0.001
Intact PTH, pg/ml109 ± 4397 ± 490.15106 ± 4480 ± 490.0060.19
Phosphorus, mg/dl3.7 ± 0.43.9 ± 0.50.093.4 ± 0.63.6 ± 0.90.340.62
Calcium, mg/dl9.0 ± 0.89.0 ± 0.60.809.1 ± 0.59.5 ± 0.90.040.15
Urine calcium/creatinine ratio, mg/mg0.023 ± 0.040.013 ± 0.020.170.025 ± 0.030.04 ± 0.070.760.36
  • a By repeated-measures two-way ANOVA with visit (baseline and end point), drug, and their interaction as factors.